Professional
Added to YB: 2025-10-13
Pitch date: 2025-09-30
CRSP [neutral]
CRISPR Therapeutics AG
-12.46%
current return
Author Info
No bio for this author
Company Info
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Market Cap
$5.3B
Pitch Price
$64.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-8.30
P/E
-9.91
EV/Sales
92.31
Sector
Biotechnology
Category
value
Orbis Global Equity Portfolio Holding: CRISPR Therapeutics AG
CRSP ((holding update): First CRISPR therapy Casgevy approved for sickle-cell disease, multibillion-dollar opportunity with Vertex partnership. Trading below cash + Casgevy value despite strong balance sheet & no patent cliff. Measured uptake curve vs conventional drugs creating valuation disconnect.
Read full article (2 min)